Prognostic Score and Nomogram for OS in LAPC

Prediction tools are designed to help physicians to predict patient’s risk profile and individual prognosis that may help to guide clinical management. They may also be used by researchers to optimize the design of future clinical trials and thus to ensure well-balanced arms for risk profile.

If you are a patient, we recommend that you use these tools only in consultation with your healthcare provider.

These tools (1,2) are based on records from LAPC patients enrolled in LAP07 trial (3,4).

You will need the following information to use the prediction tools:

  • Age: Patient’s age at the time of diagnosis.
  • Pain: Pain at diagnosis clinical exam.
  • Tumor size in mm.
  • Albumin rate in g/L
  • CA19.9: A transformation with log10 function is necessary

This LAPC nomogram can be used to predict the probability of surviving at 6, 12, 24 and 48 months.

The LAPC score can be used to identify a risk population in which your patient is located.

The two images corresponding to these tools are below :



In complement to these images a web online and smartphone application to provide individualized survival estimates from the nomogram and risk group classification for OS are under construction.


1. Vernerey D, Hammel P, Paget-Bailly S, Huguet F, Laethem JLV, Goldstein D, et al. Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): An ancillary study of the LAP 07 trial. J ClinOncol [Internet]. 2014 [cited 2014 Oct 7];32:5s(suppl; abstr 4024). Available from:

2. D. Vernerey. Prognosis model for overall survival in locally advanced pancreatic cancer (LAPC): an ancillary study of the LAP 07 trial. Annals of Oncology (2014) 25 (suppl_2):

3. Hammel P, Huguet F, Laethem J-LV, Goldstein D, Glimelius B, Artru P, et al. Comparison of chemoradiotherapy (CRT) and chemotherapy (CT) in patients with a locally advanced pancreatic cancer (LAPC) controlled after 4 months of gemcitabine with or without erlotinib: Final results of the international phase III LAP 07 study. J ClinOncol [Internet]. 2013 [cited 2014 Oct 7];31(suppl; abstr LBA4003). Available from:

4. Chemoradiotherapy Offers No Advantage in Locally Advanced Pancreatic Cancer [Internet]. ASCO Annual Meeting. [cited 2014 Oct 1]. Available from:…

5. Prognostic Score and Nomogram to predict Overall Survival in Locally Advanced Pancreatic Cancer : Dewi Vernerey1, David Goldstein, Florence Huguet2, Sophie Paget-Bailly, Jean-Luc Van Laethem, ,BengtGlimelius, Pascal Artru2, M. J. Moore, Thierry André2, Laurent Mineur, Benoist Chibaudel2, Christophe Louvet2, Pascal Hammel2, Franck Bonnetain1,2;

1- Methodological and Quality of Life in Oncology Unit, EA 3181, University Hospital of Besancon, France

2- GERCOR (Groupe Coopérateur Multidisciplinaire en Oncologie), PARIS, France Submitting

Locally Advanced Pancreatic Cancer prediction tools: Disclaimer

The prediction tools, also known as prognostic score and nomogram, located on the foundation ARCAD web site are for general health information only. The prediction tools are not to be used as a substitute for medical advice, diagnosis, or treatment of any health condition or problem.

Users of the prediction tools should not rely on information provided by the prediction tools for their own health problems. Questions should be addressed to your own physician or other healthcare provider.

You are hereby advised to consult with a physician or other professional healthcare provider prior to making any decisions, or undertaking any actions or not undertaking any actions related to any healthcare problem or issue you might have at any time, now or in the future. In using the prediction tools, you agree that foundation ARCAD nor any other party is or will be liable or otherwise responsible for any decision made or any action taken or any action not taken due to your use of any information presented in the prediction tools.